Recordbreaking BIO-Europe in Munich, but: back to 2019
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Amyl Therapeutics bags �11m Series A extension
/in News/by Thomas GabrielczykBelgian amyloid fibrils specialist Amyl Therapeutics SA has got a �11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. <br /> <br /><br […]
Evotech screens cancer candidates for Dewpoint Therapeutics
/in News/by Thomas GabrielczykGerman Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.<br /><br />
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
/in News/by Thomas GabrielczykPierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.
Scotland boosts bio-based manufacturing with �75m fund
/in News/by Thomas GabrielczykBiotech companies in Scotland�s thriving bio-based manufacturing have been invited to apply for up to �1m funding within the Launchpad programme.
Majority of EU agri-council supports NGT deregulation
/in News/by Thomas GabrielczykAt a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.
New detection method for protein degraders
/in News/by Thomas GabrielczykGerman researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
??Study: New breeding methods hardly contribute to climate protection
/in News/by Thomas GabrielczykAccording to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.
CEPI commits up to US$80m to University of Oxford to develop vaccines
/in News/by Thomas GabrielczykThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.
Pairwise and Bayer collaborate to CRISPR short-stem maize
/in News/by Thomas GabrielczykBayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System.